AbbVie to face House committee subpoena over Humira, Imbruvica pricing strategies: chairwoman

AbbVie has faced years of investigations and lawsuits over its drug pricing and patenting strategies, but lawmakers at the House Committee on Oversight and Reform haven’t been satisfied with the company’s responses to their 18-month probe. The committee's chairwoman is now planning to subpoena the company after repeated attempts at gathering info haven't yielded the results she wanted.